Scinai Immunotherapeutics Regains Nasdaq Compliance, Draws Trader Focus

Scinai Immunotherapeutics Ltd. stocks have been trading up by 15.51 percent amid heightened optimism from its latest clinical developments

Live Update At 12:33:07 EDT: On Tuesday, October 13, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 15.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SCNI has spent the past month grinding lower after a sharp spike, but it’s still holding its Nasdaq lifeline. On the daily chart, Scinai Immunotherapeutics ran from the mid‑$1.60s on 2026/09/18 to a close near $1.98 on 2026/09/23, then faded back toward the $1.30 area by 2026/10/13. That’s a textbook small‑cap biotech pop and bleed, with SCNI now trying to build a new base above the crucial $1.00 level.

Intraday on the latest session, SCNI’s 5‑minute chart shows a wild premarket range from $1.13 to a high above $3.30 before settling near $1.34 by midday. That tells traders two things: liquidity is thin, and tiny order flows can trigger huge wicks. For day traders, SCNI is a volatility vehicle, not a sleepy swing.

More Breaking News

• RKT Stock Slumps As Mr. Cooper Deal And Target Cut Rattle Traders
• SOFI Stock Slides As Price Target Cut And Insider Sale Hit Sentiment
• BKYI Stock Rockets As Gulf Partnership And FIDO Win Ignite Momentum
• EBAY Stock Holds Highs As Analysts Back Recommerce Momentum

Fundamentally, Scinai Immunotherapeutics is still an early‑stage story. Revenue is just over $1.31M, with a price‑to‑sales ratio around 1.22. Book value per share sits near $1.83, while SCNI trades below that, implying the market is discounting its assets and future cash flows. Returns on equity and assets are sharply negative, showing the company is burning capital to build its NanoAb and CDMO platforms. For active traders, SCNI is a classic speculative biotech — story‑driven, dilutive risk, and highly headline‑sensitive.

Why Traders Are Watching SCNI Now

SCNI just cleared one of the biggest landmines a small‑cap can face: Nasdaq delisting risk. Scinai Immunotherapeutics regained compliance with the exchange’s $1.00 minimum bid price rule after 19 consecutive trading days above that mark. With that, Nasdaq has closed the related compliance matter. The immediate delisting overhang is off the table, and that alone can change how traders frame the SCNI setup.

When a stock trades under $1.00, many funds, algos, and even some retail traders simply step away. Re‑establishing that $1.00 floor puts SCNI back on more screens and scanners. It also reduces the odds of a forced reverse split in the near term, which traders usually see as dilution‑friendly and trend‑killing. Now, Scinai Immunotherapeutics can shift the conversation from survival back to execution.

On the business side, SCNI is still pushing its NanoAb immunology programs while trying to scale its CDMO operations. That combination matters. Pipeline headlines can spark momentum bursts, while CDMO work can offer more steady, service‑based revenue over time. Traders watching SCNI are basically asking: does the company have enough cash, time, and execution to convert those efforts into meaningful numbers?

With total assets around $11.63M, cash of roughly $1.66M, and about 31 employees, Scinai Immunotherapeutics is lean and highly sensitive to capital markets. The restored Nasdaq compliance gives SCNI more flexibility to raise money if needed and to negotiate from a slightly stronger position. For short‑term trading, that mix of de‑risked listing status, tiny float‑style price action, and biotech catalysts keeps SCNI squarely on momentum watch lists.

Conclusion

For active traders, SCNI now sits in a cleaner, more tradable lane. The Nasdaq compliance win removes a structural threat that often crushes sentiment and volume. Scinai Immunotherapeutics spent 19 days holding above $1.00 to get there, proving that, for now, the market is willing to keep SCNI as a legit listed biotech rather than a broken penny stock.

That doesn’t change the underlying reality: Scinai Immunotherapeutics is still pre‑scale, with modest revenue, negative returns, and a balance sheet that leaves little room for big mistakes. SCNI’s story revolves around execution on its NanoAb immunology programs and the ability to grow its CDMO business into a more reliable revenue stream. Any clear progress or contracts in those areas can be powerful near‑term catalysts; any stumble can be punished quickly. For short‑term traders, that means focusing on what price and volume are actually doing in the moment rather than building grand long‑term narratives. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” In the context of SCNI, that kind of mindset keeps the emphasis on the current trend, liquidity, and catalysts instead of wishful thinking.

For traders who thrive on volatility, SCNI offers big ranges, sharp intraday swings, and a clear technical line in the sand at $1.00. But the key is discipline. As Tim Sykes likes to remind his students, “The market doesn’t owe you anything; your edge comes from preparation, not hope.” Scinai Immunotherapeutics will reward only those traders who respect the risk, track the news closely, and cut losses fast when the trade breaks.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.